Artículos del autor

solaci

Antiplatelet

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular...
solaci -
Other

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction...
solaci -
Antiplatelet

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow...
solaci -
Day 3

SOLACI-SOCIME 2018 | Primary angioplasty and cardiogenic shock

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
SOLACI

SOLACI-SOCIME 2018 | Real world supported unprotected LM PCI with impella device

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Day 3

SOLACI-SOCIME 2018 | Bio Active Stents

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Day 3

SOLACI-SOCIME 2018 | Multivascular PCI

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Day 3

SOLACI-SOCIME 2018 | PCI of the artery responsible for the infarct

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -